Tiedemann Advisors, LLC Relmada Therapeutics, Inc. Transaction History
Tiedemann Advisors, LLC
- $2.31 Billion
- Q3 2023
A detailed history of Tiedemann Advisors, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Tiedemann Advisors, LLC holds 31,715 shares of RLMD stock, worth $95,779. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,715
Previous 31,715
-0.0%
Holding current value
$95,779
Previous $78,000
21.79%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding RLMD
# of Institutions
101Shares Held
14.3MCall Options Held
82KPut Options Held
73.9K-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.24MShares$3.74 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$3.62 Million0.46% of portfolio
-
Acadian Asset Management LLC Boston, MA1.18MShares$3.57 Million0.02% of portfolio
-
Parsons Capital Management Inc974KShares$2.94 Million0.31% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $86.4M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...